Table 4 Risk factors for virologic failure
Virological failure n = 13, n/median (%/IQR) | Virological success n = 314, n/median (%/IQR) | p–value | |
|---|---|---|---|
Age, years | 46 (41–50) | 44 (38–51) | 0.82 |
Gender, male | 10 (77.0%) | 219 (70.0%) | 0.76 |
Mode of HIV infection | – | – | 1.00 |
Heterosexual | 7 (54.0%) | 162 (52.0%) | – |
MSM | 5 (38.0%) | 117 (37.0%) | – |
Others | 1 (8.0%) | 35 (11.0%) | – |
Nadir CD4 cell count (cell/mm 3 ) | 212 [166–255] | 231 [107–349] | 0.77 |
CD4 cell count at baseline (cell/mm 3 ) | 536 [405–866] | 619 [452–804] | 0.89 |
Creatinine levels at baseline (µmoL/L) | 79 [68–88] | 79 [70–90] | 0.76 |
Time since HIV infection, years | 12 (11–19) | 11 (5–17) | 0.27 |
Duration of HIV treatment, years | 9 (6–10) | 8 (4–13) | 0.77 |
Number of previous ART regimens | 4 (2–4) | 3 (2–5) | > 0.99 |
History of VF before the switch | 2 (15.0%) | 64 (20.0%) | 1.00 |
Duration of HIV RNA < 50 copies/mL before the switch, months | 21.9 (3–26) | 33.6 (13–63) | 0.05 |
INSTI base ART at time of switch | 2 (15.0%) | 66 (21.0%) | 1.00 |
PI/r based ARTat time of switch | 9 (69.2%) | 177 (56.4%) | 0.44 |
Previous M84V/I* | 4/9 (44.0%) | 27/143 (19.0%) | 0.09 |
Previous M84V/I + at least 1 other TDF RAM* (among M41L,E44D, D67N,T69D/N/S, L74V/I, L210W or T215A/C/D/E/G/H//L/N/S/V/Y/F) | 3/9 (33.3%) | 14/143 (9.8%) | 0.06 |
Previous K65R* | 0/9 (0.0%) | 1/143 (1.0%) | 1.00 |
Previous RAMs to elvitegravir (N155H)*§ | 1/9 (11.0%) | 0/143 (0.0%) | 0.06 |